116 related articles for article (PubMed ID: 1992566)
1. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.
LaRocca RV; Cooper MR; Uhrich M; Danesi R; Walther MM; Linehan WM; Myers CE
Urol Clin North Am; 1991 Feb; 18(1):123-9. PubMed ID: 1992566
[TBL] [Abstract][Full Text] [Related]
2. Suramin: prototype of a new generation of antitumor compounds.
La Rocca RV; Stein CA; Myers CE
Cancer Cells; 1990 Apr; 2(4):106-15. PubMed ID: 2202382
[TBL] [Abstract][Full Text] [Related]
3. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
[TBL] [Abstract][Full Text] [Related]
4. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
[TBL] [Abstract][Full Text] [Related]
5. [Influence of suramin on the proliferation of prostatic carcinoma cells PC-3M].
Xing YF; Lu GC; Xiao YJ; Zeng FQ; Zhang QJ; Feng W
Zhonghua Nan Ke Xue; 2003 Aug; 9(5):338-40. PubMed ID: 14513638
[TBL] [Abstract][Full Text] [Related]
6. UK studies on suramin therapy in hormone resistant prostate cancer.
Kehinde EO; Terry TR; Mistry N; Horsburgh T; Sandhu DP; Bell PR
Cancer Surv; 1995; 23():217-29. PubMed ID: 7621460
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):631-4. PubMed ID: 9681533
[TBL] [Abstract][Full Text] [Related]
8. Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Piscitelli SC; Forrest A; Lush RM; Ryan N; Whitfield LR; Figg WD
Pharmacotherapy; 1997; 17(3):431-7. PubMed ID: 9165547
[TBL] [Abstract][Full Text] [Related]
9. Suramin, a novel antitumor compound.
La Rocca RV; Stein CA; Danesi R; Myers CE
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):893-8. PubMed ID: 2285603
[TBL] [Abstract][Full Text] [Related]
10. Suramin and serum insulin-like growth factor levels in metastatic cancer patients.
Miglietta L; Barreca A; Repetto L; Costantini M; Rosso R; Boccardo F
Anticancer Res; 1993; 13(6B):2473-6. PubMed ID: 8135485
[TBL] [Abstract][Full Text] [Related]
11. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells.
Coffey RJ; Leof EB; Shipley GD; Moses HL
J Cell Physiol; 1987 Jul; 132(1):143-8. PubMed ID: 3496343
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
Bok RA; Halabi S; Fei DT; Rodriquez CR; Hayes DF; Vogelzang NJ; Kantoff P; Shuman MA; Small EJ
Cancer Res; 2001 Mar; 61(6):2533-6. PubMed ID: 11289126
[TBL] [Abstract][Full Text] [Related]
13. Suramin-induced skin reactions.
O'Donnell BP; Dawson NA; Weiss RB; Myers CE; James WD
Arch Dermatol; 1992 Jan; 128(1):75-9. PubMed ID: 1531404
[TBL] [Abstract][Full Text] [Related]
14. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Arah IN; Dixon SC; Horti J; Figg WD
Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
[TBL] [Abstract][Full Text] [Related]
15. Effect of suramin on human prostate cancer cells in vitro.
La Rocca RV; Danesi R; Cooper MR; Jamis-Dow CA; Ewing MW; Linehan WM; Myers CE
J Urol; 1991 Feb; 145(2):393-8. PubMed ID: 1824865
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
17. Suramin's development: what did we learn?
Kaur M; Reed E; Sartor O; Dahut W; Figg WD
Invest New Drugs; 2002 May; 20(2):209-19. PubMed ID: 12099581
[TBL] [Abstract][Full Text] [Related]
18. [The enhancement of the chemotherapeutic effects on human prostate cancer cell--the combination with the growth factor interaction inhibitor (suramin)].
Suzuki Y; Miwa Y; Akino H; Fujita T; Saikawa S; Kanimoto Y; Okada K
Hinyokika Kiyo; 1993 Dec; 39(12):1215-20. PubMed ID: 8285172
[TBL] [Abstract][Full Text] [Related]
19. Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
Tisdale JF; Figg WD; Reed E; McCall NA; Alkins BR; Horne MK
Am J Hematol; 1996 Feb; 51(2):152-7. PubMed ID: 8579057
[TBL] [Abstract][Full Text] [Related]
20. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
Zhang Y; Song S; Yang F; Au JL; Wientjes MG
J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]